

#### HIV ascertainment through repeat home-based testing in the context of a Treatment as Prevention trial (ANRS 12249 TasP) in rural South Africa

Joseph Larmarange, Joanna Orne-Gliemann, Éric Balestre, Collins Iwuji, Nonhlanhla Okesola, Marie-Louise Newell, François Dabis, France Lert

#### ▶ To cite this version:

Joseph Larmarange, Joanna Orne-Gliemann, Éric Balestre, Collins Iwuji, Nonhlanhla Okesola, et al.. HIV ascertainment through repeat home-based testing in the context of a Treatment as Prevention trial (ANRS 12249 TasP) in rural South Africa. HIV Research for Prevention conference (HIV R4P), Oct 2014, Cape Town, South Africa. ird-04119688

#### HAL Id: ird-04119688 https://ird.hal.science/ird-04119688

Submitted on 6 Jun2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Antiretroviral Treatment as Prevention • ANRS 12249 Ukuphila kwami, ukuphila kwethu (my health for our health)



Among the 12,894 registered individuals, 9,927 (77.0%, 95% CI: 72.6% - 80.9%) have been contacted at least once; of these, 76.8% (95% CI: 73.0% - 80.3%) have been HIV ascertained at first contact.

A second contact creates an opportunity to find individuals not ascertained at first contact, the 'ever ascertained rate' increased from 76.8% after one contact to 89.2% after two contacts (+12.4, 5237/5868, 95% Cl: 86.7% - 91.3%).

Among individuals tested negative at first contact, repeat ascertainment rate at second contact was 85.1% (95% CI: 82.2% -87.5%).









# HIV ASCERTAINMENT THROUGH REPEAT HOME-BASED TESTING IN THE CONTEXT OF A TREATMENT-AS-PREVENTION TRIAL (ANRS 12249 TASP) IN RURAL SOUTH AFRICA

## Joseph Larmarange<sup>1,2\*</sup> Joanna Orne-Gliemann<sup>3\*</sup> Éric Balestre<sup>3</sup> Collins Iwuji<sup>1</sup> Nonhlanhla Okesola<sup>1</sup> Marie-Louise Newell<sup>4</sup> François Dabis<sup>3</sup> France Lert<sup>5</sup> for the TasP ANRS 12249 Study Group

1 Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa. 2 Centre Population et Développement (CEPED UMR 196 Université Paris Descartes Ined IRD), France. 3 INSERM / University of Bordeaux, ISPED, Centre Inserm U897- Épidemiologie-Biostatistique, France. 4 Faculty of Medicine, University of Southampton, United Kingdom. 5 Centre de recherche en Épidémiologie et Santé des Populations (CESP, Inserm Unité 1018), Villejuif, France.

## CONTEXT

The ANRS 12249 TasP trial evaluates whether HIV testing of all members of a community, followed by immediate antiretroviral treatment (ART) for infected people, will prevent onward sexual transmission and reduce HIV incidence at population level. Ascertaining the HIV status of a high proportion of the population regularly and repeatedly is key to the success of any universal test and treat strategy, as the first step of the HIV cascade.

HIV ascertainment, defined as having taken a rapid HIV test (invalidate and indeterminate results excluded) or self-reporting being HIV-positive, is a process indicator measuring the capacity of the trial to identify the HIV status of the participants and, if required, to refer them to a dedicated trial clinic.

A cluster-randomised trial is being implemented using a phased-approach in the Hlabisa sub-district (KwaZulu Natal, South Africa) where more than 20% of adults are living with HIV. The trial started in March 2012 and is implemented in 10 clusters (5×2) for the first phase to assess the feasibility and acceptability of the test and treat strategies. The HIV testing strategy consists of the implementation of 6-monthly rounds of home-based HIV counselling and testing by dedicated counsellors.

Between March 2012 and March 2014, we have implemented three rounds of home-based HIV counselling and testing in four local communities (clusters) and two rounds in six additional clusters (opened in 2013). At each home visit, individual questionnaires are administered to each consenting participant aged 16 years old or more, who is also offered rapid HIV test.

We report on preliminary results of HIV ascertainment rates at first and second contact, and individual and household-level associated factors.

## **DISCUSSION / CONCLUSION**

Acceptance of regular and frequent HIV testing is key to the community-based efficacy of treatment-as-prevention initiatives (universal test and treat) in settings with very high incidence.

Our preliminary data show that, as long as individuals are successfully re-contacted, acceptability of repeat home-based HIV testing is high (85%) among individuals previously tested negative at home. It is important to stress that only two to three rounds of home-based HIV testing have been implemented to date and it is possible that a participation fatigue will emerge over time.

Our factors analysis show that home-based testing may not capture and enroll young and active populations, especially men. Lower chance of HIV ascertainment among adults aged 20 to 40 years and among the higher educated suggests that this strategy might be less acceptable among people who can possibly access HIV testing elsewhere.

Although statistical significance of the associations at second contact is less, patterns looks similar between ascertainment at first contact and at second contact among individuals not ascertained at first contact.

Differences between those ascertained and not ascertained at second contact among those tested negative at first contact are minimized: one of the keys to engaging individuals on a repeat HIV testing pathway within the trial remains the acceptability of the first home-based HIV test.

The effect of risky sexual behaviour seems to depend on sex: among men, a more self-reported risky behaviour is associated with increased test refusal, while the opposite is observed among women. Additional analyses are required to improve our understanding of the sexual activity and behaviour of these individuals who declined home-based HIV testing despite several attempts at contacting them and were thus never ascertained. This will help assess to what extent repeated home-based HIV testing campaigns could be an efficient strategy to reach the populations most at risk of transmitting HIV, in particular mobile individuals.

Repeat home-based HIV testing appears as one of the effective strategies to achieve a high level of testing coverage in these high prevalence rural areas. However, combined HIV testing approaches could be required to achieve universal testing in socially heterogeneous communities.

TASP STUDY GROUP (alphabetical order): Till Barnighausen, Sylvie Boyer, Alexandra Calmy, Marie-Laure Chaix, Francois Dabis (co-PI), Rosemary Dray-Spira, Ken Freedberg, John Imrie, Collins Iwuji (South Trial Coordinator/Trial Physician), Sophie Karcher, Joseph Larmarange, France Lert, Richard Lessells, Kevi Naidu, Colin Newell, Marie-Louise Newell (co-PI), Nonhlanhla Okesola, Tulio de Oliviera, Joanna Orne-Gliemann (North Trial Coordinator), Deenan Pillay (co-PI), Bruno Spire, Frank Tanser, Rodolphe Thiebaut, Johannes Viljoen, Thembelihle Zuma.

ACKNOWLEDGEMENTS: The French National Agency for Aids and Viral Hepatitis Research (ANRS) is the sponsor of the TasP trial. The ANRS and the Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ) GmbH provided funding for first phase of the trial. The trial is conducted with the support of MERCK & Co. Inc and Gilead Sciences that provided Atripla® drug supply. The Africa Centre receives core funding from the Wellcome Trust, which provides the basis for the population- and clinic-based research at the Centre.

Rapid tested negative at second contac n=393 (69.6%)

Rapid tested positive nt second contact n=79 (14.0%)

Self-reported HIV+ at second contac n=93 (16.5%)

RT refused (n=629 RT invalid (n=2)

Sex ് men ♀ women Age at 1<sup>st</sup> contac 15-19 20-29 30-39 40-49 50-59 60 + missing **Educational level** completed secondary some secondary primary or less / don<sup>3</sup> missing Household's assets low middle high missing HIV test before first of < 6 months 6 to 12 months > 12 months never tested missing / refused Sexual partner(s) las 2 sexual partners or r 1 sexual partner† none / never had sex missing / refused / de

Condom use at last i yes no †

never had sex

missing †

Knowing someone F yes missing









## FACTORS ASSOCIATED WITH HIV ASCERTAINMENT

|               | Ascertainment at 1 <sup>st</sup> contact |                     |           | Ascertainment at 2 <sup>nd</sup> contact<br>among tested negative<br>at first contact |      |           | Ascertainment at 2 <sup>nd</sup> contact<br>among not ascertained<br>at first contact |      |           |
|---------------|--|---------------------|-----------|---|------|-----------|---|------|-----------|
|               | (n=9,927)                                |                     | (n=3,326) |   |      | (n=1,196) |   |      |           |
|               | %  | aOR                 | 95% CI    | %   | aOR  | 95% CI    | %   | aOR  | 95% CI    |
|               | ***                                      | **                  |           | **  | ***  |           | -   |      |           |
|               | 74.1                                     | 1                   |           | 82.3  | 1    |           | 46.6  |      |           |
|               | 78.1                                     | 2.52                | 1.54-4.11 | 86.2  | 1.29 | 1.05-1.59 | 47.5  |      |           |
|               | ***                                      | ***                 |           | **  | ***  |           | ***   | **   |           |
|               | 78.5                                     | 1                   |           | 81.7  | 1    |           | 53.8  | 1    |           |
|               | 70.4                                     | 0.66                | 0.55-0.79 | 81.2  | 0.94 | 0.70-1.26 | 37.7  | 0.63 | 0.41-0.98 |
|               | 77.0                                     | 0.77                | 0.62-0.95 | 83.9  | 1.12 | 0.74-1.68 | 54.6  | 1.16 | 0.70-1.91 |
|               | 85.1                                     | 0.95                | 0.74-1.23 | 87.1  | 1.44 | 0.98-2.11 | 48.3  | 0.61 | 0.34-1.10 |
|               | 85.4                                     | 0.89                | 0.68-1.18 | 87.5  | 1.49 | 1.05-2.11 | 50.0  | 0.56 | 0.29-1.05 |
|               | 86.3                                     | 0.98                | 0.75-1.30 | 87.7  | 1.55 | 1.15-2.08 | 61.7  | 0.96 | 0.52-1.78 |
|               | 39.2                                     | 0.57                | 0.41-0.79 | 90.6  | 2.24 | 0.86-5.83 | 23.4  | 0.52 | 0.20-1.37 |
|               | ***                                      | ***                 |           | **  |      |           | ***   | ***  |           |
| / higher      | 71.8                                     | 1                   |           | 81.5  |      |           | 37.6  | 1    |           |
|               | 78.5                                     | 1.32                | 1.15-1.50 | 83.2  |      |           | 54.1  | 1.89 | 1.33-2.69 |
| t know        | 87.6                                     | 2.23                | 1.87-2.67 | 87.4  |      |           | 61.0  | 2.81 | 1.72-4.59 |
|               | 9.8                                      | 1.55                | 0.75-3.22 | 77.8  |      |           | 4.2   | 0.87 | 0.14-5.54 |
| core category | -  |                     |           | -   |      |           | *   |      |           |
|               | 77.2                                     |                     |           | 85.7  |      |           | 51.3  |      |           |
|               | 77.0                                     |                     |           | 84.4  |      |           | 47.8  |      |           |
|               | 75.8                                     |                     |           | 85.1  |      |           | 38.9  |      |           |
|               | 86.8                                     |                     |           | 70.0  |      |           | 25.0  |      |           |
| ontact ‡      | ***                                      | ***                 |           |   |      |           |   |      |           |
|               | 68.4                                     | 1                   |           |   |      |           |   |      |           |
|               | 85.3                                     | 2.57                | 2.18-3.03 |   |      |           |   |      |           |
|               | 86.0                                     | 2.54                | 2.22-2.90 |   |      |           |   |      |           |
|               | 81.2                                     | 1.67                | 1.42-1.96 |   |      |           |   |      |           |
|               | 19.1                                     | 1.69                | 1.05-2.71 |   |      |           |   |      |           |
| 12 months     | ***                                      | **                  |           | -   |      |           | ***   |      |           |
| nore          | 75.5                                     | 1                   |           | 81.9  |      |           | 43.1  |      |           |
|               | 80.7                                     | ơ 1.34              | 1.08-1.67 | 85.7  |      |           | 49.4  |      |           |
|               |  | ♀ 0.5 <i>5</i>      | 0.35-0.85 |   |      |           |   |      |           |
|               | 82.0                                     | <b>් 2.25</b>       | 1.38-3.68 | 85.5  |      |           | 52.8  |      |           |
|               |  | 우 <b>0.3</b> 9      | 0.24-0.63 |   |      |           |   |      |           |
| on't know     | 44.9                                     | ♂ <b>0.9</b> 3      | 0.58-1.50 | 80.6  |      |           | 30.4  |      |           |
|               |  | ♀ 0.35              | 0.21-0.59 |   |      |           |   |      |           |
| ntercourse    | ***                                      | **                  |           | -   |      |           | ***   |      |           |
|               | 76.8                                     | 1                   |           | 82.8  |      |           | 43.8  |      |           |
|               | 82.1                                     | <b>് 0.97</b>       | 0.75-1.25 | 86.1  |      |           | 52.3  |      |           |
|               |  | ♀ 1 <b>.0</b> 8     | 0.92-1.26 |   |      |           |   |      |           |
|               | 78.0                                     | o <sup>*</sup> 3.21 | 1.74-5.91 | 83.0  |      |           | 49.1  |      |           |
|               |  | Ŷ 1.53              | 1.10-2.14 |   |      |           |   |      |           |
|               | 42.1                                     | o <sup>*</sup> 0.74 | 0.37-1.49 | 83.0  |      |           | 26.3  |      |           |
|               |  | Ŷ 1.08              | 0.77-1.52 |   |      |           |   |      |           |
| IV+ in family | ***                                      | ***                 |           | *   |      |           | ***   | *    |           |
|               | 79.1                                     | 1                   |           | 84.3  |      |           | 49.8  | 1    |           |
|               | 83.4                                     | 1.29                | 1.14-1.46 | 87.3  |      |           | 50.4  | 1.04 | 0.77-1.40 |
|               | 1.8                                      | 0.01                | 0.01-0.02 |   |      |           | 1.5   | 0.03 | 0.00-0.43 |

%: HIV ascertainment rate within modality (univariable analysis). aOR: adjusted odd ratio (multivariable analysis). Cl: confidence interval (odd ratio). -p > 0.05; \* 0.01  $; ** 0.001 <math>; *** <math>p \le 0.001$  (Chi<sup>2</sup> test for univariable; Wald or log likelihood test for multivariable) *†* stratified by sex (multivariable analysis); *‡* variable used only for first contact analysis.

Only variables with p≤0.20 in univariable analysis have been included in multivariable logistic models using a step-by-step backwards method (Wald criterion). Interactions between sex and others risk factors were tested and potential confounding were checked. Clusters effect was taken into account by using random effects models (except for first model who did not converge).